Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT01402284
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 5
- Registration Number
- NCT01401322
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL
- Conditions
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT01400685
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
- Conditions
- Interventions
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT01393964
- Locations
- 🇺🇸
University Of Maryland, Baltimore, Maryland, United States
🇺🇸Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States
🇺🇸Tennessee Oncology, Pllc, Nashville, Tennessee, United States
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01383928
- Locations
- 🇺🇸
Virginia Cancer Specialists PC, Fairfax, Virginia, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 64
- Registration Number
- NCT01378091
- Locations
- 🇺🇸
Cornell Weill Medical Center, New York, New York, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT01375140
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-06-15
- Last Posted Date
- 2018-12-10
- Target Recruit Count
- 14
- Registration Number
- NCT01374217
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2019-08-06
- Target Recruit Count
- 17
- Registration Number
- NCT01373294
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 88
- Registration Number
- NCT01358734
- Locations
- 🇺🇸
(240) Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸(160) The Western Pennsylvania Hospital- Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸(200) Coastal Integrative Cancer Care, San Luis Obispo, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.